Paper1997108
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G and 3 others. Br J Cancer, 1991. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Papers, record 1997108. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1997108
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Renal Cell | Major topic |
| Interferon-alpha | Major topic |
| Interleukin-2 | Major topic |
| Kidney Neoplasms | Major topic |
| Melanoma | Major topic |
| Adult | |
| Drug Administration Schedule | |
| Female | |
| HLA-DR Antigens | |
| Humans | |
| Interferon alpha-2 | |
| Killer Cells, Lymphokine-Activated | |
| Killer Cells, Natural | |
| Male | |
| Middle Aged | |
| Recombinant Proteins |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4056843 | Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. | J Clin Oncol | 1985 | https://conductscience.org/library/papers/4056843 | PubMed |
| 2 | 2390468 | Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. | Br J Cancer | 1990 | https://conductscience.org/library/papers/2390468 | PubMed |
| 3 | 3828990 | Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines. | Cancer Res | 1987 | https://conductscience.org/library/papers/3828990 | PubMed |
| 4 | 3497883 | In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. | Int J Cancer | 1987 | https://conductscience.org/library/papers/3497883 | PubMed |
| 5 | 3258138 | Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. | Ann Intern Med | 1988 | https://conductscience.org/library/papers/3258138 | PubMed |
| 6 | 3285747 | NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. | Ann Intern Med | 1988 | https://conductscience.org/library/papers/3285747 | PubMed |
| 7 | 3259674 | Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. | N Engl J Med | 1988 | https://conductscience.org/library/papers/3259674 | PubMed |
| 8 | 3131876 | Interleukin-2: inception, impact, and implications. | Science | 1988 | https://conductscience.org/library/papers/3131876 | PubMed |
| 9 | 2493053 | Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. | J Immunol | 1989 | https://conductscience.org/library/papers/2493053 | PubMed |
| 10 | 2647913 | A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2647913 | PubMed |
| 11 | 2787749 | Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. | Eur J Cancer Clin Oncol | 1989 | https://conductscience.org/library/papers/2787749 | PubMed |
| 12 | 2809685 | Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2809685 | PubMed |
| 13 | 2685181 | Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2685181 | PubMed |
| 14 | 2598190 | The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2598190 | PubMed |
| 15 | 181845 | Selective in vitro growth of T lymphocytes from normal human bone marrows. | Science | 1976 | https://conductscience.org/library/papers/181845 | PubMed |
| 16 | 6175788 | Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity. | J Natl Cancer Inst | 1982 | https://conductscience.org/library/papers/6175788 | PubMed |
| 17 | 6403867 | Structure and expression of a cloned cDNA for human interleukin-2. | Nature | 1983 | https://conductscience.org/library/papers/6403867 | PubMed |
| 18 | 6413638 | Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. | J Exp Med | 1983 | https://conductscience.org/library/papers/6413638 | PubMed |
| 19 | 3873953 | Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3873953 | PubMed |
| 20 | 2156163 | An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. | N Engl J Med | 1990 | https://conductscience.org/library/papers/2156163 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31340613 | Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31340613 | PubMed |
| 30691103 | Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis. | J Clin Med | 2019 | https://conductscience.org/library/papers/30691103 | PubMed |
| 28337194 | IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System. | Front Immunol | 2017 | https://conductscience.org/library/papers/28337194 | PubMed |
| 23982524 | The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. | Nat Rev Clin Oncol | 2013 | https://conductscience.org/library/papers/23982524 | PubMed |
| 8408187 | Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy. | J Cancer Res Clin Oncol | 1993 | https://conductscience.org/library/papers/8408187 | PubMed |
| 8306366 | Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/8306366 | PubMed |
| 7678979 | Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. | Br J Cancer | 1993 | https://conductscience.org/library/papers/7678979 | PubMed |
| 1419647 | Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. | Br J Cancer | 1992 | https://conductscience.org/library/papers/1419647 | PubMed |
| 1418698 | Clinical toxicity of interleukin-2. | Drug Saf | 1992 | https://conductscience.org/library/papers/1418698 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALPK1 | 80216 | PubTator's text mining | https://conductscience.org/library/genes/80216 | NCBI Gene |
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1997108
GET https://conductscience.org/api/papers/v1/1997108/references?page=2